Discussion: A relatively high prevalence of the
N236T mutation was recorded in the study patients, which is frequently associated with the
A181T/V mutation, a combination that confers decreased efficacy of tenofovir in vitro and was linked to a delayed response to TDF/TAF in patients with high viral loads, or with the compensatory
L80V mutation, reported to be associated with LAM and ADV resistance.